Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 1/2012

01-02-2012 | Original Paper

Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands

Authors: I. Lenoir-Wijnkoop, W. M. C. van Aalderen, G. Boehm, D. Klaassen, A. B. Sprikkelman, M. J. C. Nuijten

Published in: The European Journal of Health Economics | Issue 1/2012

Login to get access

Abstract

The objective of this study was to assess the cost-effectiveness of the use of prebiotics for the primary prevention of atopic dermatitis in The Netherlands. A model was constructed using decision analytical techniques. The model was developed to estimate the health economic impact of prebiotic preventive disease management of atopic dermatitis. Data sources used include published literature, clinical trials and official price/tariff lists and national population statistics. The comparator was no supplementation with prebiotics. The primary perspective for conducting the economic evaluation was based on the situation in The Netherlands in 2009. The results show that the use of prebiotics infant formula (IMMUNOFORTIS®) leads to an additional cost of € 51 and an increase in Quality Adjusted Life Years (QALY) of 0.108, when compared with no prebiotics. Consequently, the use of infant formula with a specific mixture of prebiotics results in an incremental cost-effectiveness ratio (ICER) of € 472. The sensitivity analyses show that the ICER remains in all analyses far below the threshold of € 20,000/QALY.

Conclusion

This study shows that the favourable health benefit of the use of a specific mixture of prebiotics results in positive short- and long-term health economic benefits. In addition, this study demonstrates that the use of infant formula with a specific mixture of prebiotics is a highly cost-effective way of preventing atopic dermatitis in The Netherlands.
Literature
1.
2.
Kunz, B., Oranje, A.P., Labreze, L., et al.: Clinical validation and guidelines for the SCORAD index: consensus report of the European task force on atopic dermatitis. Dermatology 195, 10–19 (1997)
3.
4.
Levy, R.M., Gelfand, J.M., Yan, A.C.: The epidemiology of atopic dermatitis. Clin. Dermatol. 21, 109–115 (2003)PubMedCrossRef
5.
6.
The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 351, 1225–1232 (1998)
7.
Schultz-Larsen, F.: Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J. Am. Acad. Dermatol. 28, 719–723 (1993)PubMedCrossRef
8.
Butland, B.K., Strachan, D.P., Lewis, S., Bynner, J., Butler, N., Britton, J.: Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. BMJ 315, 717–721 (1997)PubMedCrossRef
9.
Reitamo, S., Remitz, A., Haahtela, T.: Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy 64, 503–504 (2009)
10.
Carroll, C.L., Balkrishnan, R., Feldman, S.R., et al.: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr. Dermatol. 22, 192–199 (2005)
11.
Schmid-Ott, G., Kuensebeck, H.W., Jaeger, B., et al.: Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta. Derm. Venereol. 79, 443–447 (1999)
12.
Ben-Gashir, M.A.: Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood. Curr. Opin. Allergy Clin. Immunol. 3, 369–373 (2003)PubMedCrossRef
13.
Finlay, A.Y., Khan, G.K.: Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210–216 (1994)PubMedCrossRef
14.
Lewis-Jones, M.S., Finlay, A.Y.: The children’s dermatology life quality index (CDLQI): initial validation and practical use. Br. J. Dermatol. 32, 942–949 (1995)
15.
Abeni, D., Picardi, A., Pasquini, P., et al.: Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 204, 43–49 (2002)
16.
Absolon, C.M., Cottrell, D., Eldridge, S.M., et al.: Psychological disturbance in atopic eczema: the extent of the problem in school-aged children. Br. J. Dermatol. 137, 241–245 (1997)
17.
Beattie, P.E., Lewis-Jones, M.S.: A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br. J. Dermatol. 155, 145–151 (2006)PubMedCrossRef
18.
Ben-Gashir, M.A., Seed, P.T., Hay, R.J.: Quality of life and disease severity are correlated in children with atopic dermatitis. Br. J. Dermatol. 150, 284–290 (2004)PubMedCrossRef
19.
Chamlin, S.L., Cella, D., Frieden, I.J., et al.: Development of the childhood atopic dermatitis impact scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J. Invest. Dermatol. 125, 1106–1111 (2005)
20.
Holm, E.A., Wulf, H.C., Stegmann, H., et al.: Life quality assessment among patients with atopic eczema. Br. J. Dermatol. 154, 719–725 (2006)
21.
Kiebert, G., Sorensen, S.V., Revicki, D., et al.: Atopic dermatitis is associated with a decrement in health-related quality of life. Int. J. Dermatol. 41, 151–158 (2002)
22.
Lewis-Jones, S.: Measuring the burden of atopic eczema in young children and the family unit. J. Invest. Dermatol. 125, viii (2005)
23.
Lundberg, L., Johannesson, M., Silverdahl, M., et al.: Health related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta. Derm. Venereol. 80, 430–434 (2000)
24.
Sampogna, F., Picardi, A., Chren, M.M. et al.: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom. Med. 66, 620–624 (2004)
25.
Wittkowski, A., Richards, H.L., Griffiths, C.E. et al.: The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J. Psychosom. Res. 57, 195–200 (2004)
26.
Brenninkmeijer, E.E.A., Legierse, C.M., Sillevis Smitt, J.H., Last, B.F., Grootenhuis, M.A., Bos, J.D.: The course of life of patients with childhood atopic dermatitis. Allergy 64, 840–848 (2009)
27.
Wille, N., Badia, X., Bonsel, G., Burström, K., Cavrini, G., Devlin, N., Egmar, A.C., Greiner, W., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Scalone, L., Ravens-Sieberer, U.: Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual. Life Res. 19(6), 875–886 (2010)PubMedCrossRef
28.
Rhodes, H.L.: Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J. Allergy Clin. Immunol. 108, 720–725 (2001)PubMedCrossRef
29.
Kulig, M., Bergmann, R., Klettke, U., Wahn, V., Tacke, U., Wahn, U., et al.: Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J. Allergy Clin. Immunol. 103, 1173–1179 (1999)
30.
Spergel, J.H., Paller, A.S.: Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112, S118–S127 (2003)PubMedCrossRef
31.
Liu, A.H., Martinez, F.D., Taussig, L.M.: Natural history of allergic diseases and asthma. In: Leung, D.Y.M., Sampson, H.A., Geha, R.S., Szefler, S.J. (eds.) Pediatric Allergy: Principles and Practice, pp. 10–22. Elsevier, Philadelphia (2003)
32.
Bergmann, R.L., Edenharter, G., Bergmann, K.E., Forster, J., et al.: Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin. Exp. Allergy 28, 965–970 (1998)
33.
Gustafsson, D., Sjoberg, O., Foucard, T.: Development of allergies and asthma in infants and young children with atopic dermatitis—a prospective followup to 7 years of age. Allergy 55, 240–245 (2000)PubMedCrossRef
34.
Van der Hulst, A.E., Klip, H., Brand, P.L.: Risk of developing asthma in young children with atopic eczema: a systematic review. J. Allergy Clin. Immunol. 120, 565–569 (2007)
35.
Hanifin, J.M., Reed, M.L.: A population-based survey of eczema prevalence in the United States. Dermatitis 18, 82–91 (2007)PubMedCrossRef
36.
Martin Fernandez-Mayoralas, D., Martin Caballero, J.M., Garcia-Marcos Alvarez, L.: Association between atopic dermatitis, allergic rhinitis and asthma in schoolchildren aged 13–14 years old. An. Pediatr. (Barc) 60, 236–242 (2004)
37.
Hakansson, K., Thomsen, SF., Ulrik, C.S., Porsbjerg, C., et al.: Increase in the prevalence of rhinitis among Danish children from 1986 to 2001. Pediatr. Allergy Immunol. 18, 154–159 (2007)
38.
39.
Mancini, A.J., Kaulback, K., Chamlin, S.L.: The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr. Dermatol. 25, 1–6 (2008)PubMedCrossRef
40.
Kalliomäki, M., Salminen, S., Poussa, T., Arvilommi, H., Isolauri, E.: Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 361, 1869–1871 (2003)PubMedCrossRef
41.
Kalliomäki, M., Salminen, S., Poussa, T., Isolauri, E.: Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 119, 1019–1021 (2007)PubMedCrossRef
42.
Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E., et al.: A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 122, 788–794 (2008)
43.
Moro, G., Arslanoglu, S., Stahl, B., Jelinek, J., Wahn, U., Boehm, G.: A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis durig the first six months of age. Arch. Dis. Child. 91, 814–819 (2006)PubMedCrossRef
44.
Arslanoglu, S., Moro, G., Schmitt, J., Tandoi, L., Rizzardi, S., Boehm, G.: Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J. Nutr. 138, 1091–1095 (2008)
45.
Weinstein, M.C., Fineberg, H.V.: Clinical Decision Analysis, pp. 228–265. WB Saunders Co, Philadelphia, PA (1980)
46.
Lenoir-Wijnkoop, I., Dapoigny, M., Dubois, D., van Ganse, E., Gutiérrez-Ibarluzea, I., Hutton, J., Jones, P., Mittendorf, T., Poley, M.J., Salminen, S., Nuijten, M.J.: Nutrition economics—characterising the economic and health impact of nutrition. Br. J. Nutr. 1–9 (2010). doi:10.​1017/​s000711451000304​1
47.
Nuijten, M.J.C., Al, M., Rutten, F.: In search for more confidence in health economic modelling (thesis) (2003)
48.
Richtlijnen voor farmaco-economisch onderzoek. Geactualiseerde versie (April 2006). College voor zorgverzekeringen. Diemen. Maart 2006
49.
50.
Lowe, A.J., Abramson, M.J., Hosking, C.S., Carlin, J.B., et al.: The temporal sequence of allergic sensitization and onset of infantile eczema. Clin. Exp. Allergy 37, 536–542 (2007)
51.
Poole, D., Chambers, C., Sidhu, M.K., Currie, C.J.: Health-related utility among adults with atopic dermatitis treated with tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic_CONTROL study. Br. J. Dermatol. 161, 1335–1340 (2009)
52.
Greenough, A., Alexander, J., Burgess, S., Bytham, J., Chetcuti, P.A., Hagan, J., Lenney, W., Melville, S., Shaw, N.J., Boorman, J., Coles, S., Turner, J., Pang, F.: Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch. Dis. Child. 89(7), 673–678 (2004)PubMedCrossRef
53.
Malhotra, A., Krilov, L.: Influenza and respiratory syncytial virus.: Update on infection, management and prevention. Pediatr. Clin. North Am. 47, 353–372 (2000)PubMedCrossRef
54.
Welliver, R., Duffy, L.: The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing and pulmonary functions at age 7–8 years. Pediatr. Pulmonol. 15, 19–27 (1993)PubMedCrossRef
55.
Su, J.C., Kemp, A.S., Varigos, G.A., Nolan, T.M.: Atopic eczema: its impact on the family and financial cost. Arch. Dis. Child. 76, 159–162 (1997)PubMedCrossRef
56.
Hoogendoorn, E.J.I., Feenstra, T.L., Rutten-van Mölken, M.P.M.H.: Inventarisatie van het gebruik en de kosten van zorg voor astma en COPD in Nederland. RIVM rapport 260604001 (2004)
57.
Reid, P., Lewis-Jones, M.S.: Sleep difficulties and their management in preschoolers with atopic eczema. Clin. Exp. Dermatol. 20, 38–41 (1995)PubMedCrossRef
58.
Kemp, A.S.: Atopic eczema: its social and financial costs. J. Paediatr. Child Health 35, 229–231 (1999)
59.
Lenny W.: The burden of pediatric asthma. Pediatr. Pulmonol. Suppl. 15, 13–16 (1997)
60.
Metadata
Title
Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
Authors
I. Lenoir-Wijnkoop
W. M. C. van Aalderen
G. Boehm
D. Klaassen
A. B. Sprikkelman
M. J. C. Nuijten
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 1/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0289-4

Other articles of this Issue 1/2012

The European Journal of Health Economics 1/2012 Go to the issue

Original Paper

The convergence of health care financing structures: empirical evidence from OECD-countries

Original paper

Future costs in cost-effectiveness analysis: an empirical assessment

Original Paper

The impact of presumed consent laws and institutions on deceased organ donation

Original Paper

Spillover effects of supplementary on basic health insurance: evidence from the Netherlands

Original Paper

Decomposing the determinants of health care expenditure: the case of Spain

Original Paper

The cost of multiple sclerosis in Norway